Cargando…

Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China

The World Health Organization guidelines recommend lopinavir/ritonavir (LPV/r) as a second-line antiretroviral therapy (ART) for HIV-infected adults in middle-income and low-income countries as a protease inhibitor boost based on clinical trials; however, the real-world safety and efficacy remain un...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xiaojie, Xu, Liumei, Sun, Lijun, Gao, Guiju, Cai, Weiping, Liu, Yanfen, Ding, Haibo, Wei, Hongxia, Ma, Ping, Wang, Min, Liu, Shuiqing, Chen, Yaokai, Chen, Xiaohong, Zhao, Qingxia, Yu, Jianhua, Song, Yuxia, Chen, Hui, Wu, Hao, Qin, Shanfang, Li, Linghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917650/
https://www.ncbi.nlm.nih.gov/pubmed/31920648
http://dx.doi.org/10.3389/fphar.2019.01455
_version_ 1783480445093019648
author Huang, Xiaojie
Xu, Liumei
Sun, Lijun
Gao, Guiju
Cai, Weiping
Liu, Yanfen
Ding, Haibo
Wei, Hongxia
Ma, Ping
Wang, Min
Liu, Shuiqing
Chen, Yaokai
Chen, Xiaohong
Zhao, Qingxia
Yu, Jianhua
Song, Yuxia
Chen, Hui
Wu, Hao
Qin, Shanfang
Li, Linghua
author_facet Huang, Xiaojie
Xu, Liumei
Sun, Lijun
Gao, Guiju
Cai, Weiping
Liu, Yanfen
Ding, Haibo
Wei, Hongxia
Ma, Ping
Wang, Min
Liu, Shuiqing
Chen, Yaokai
Chen, Xiaohong
Zhao, Qingxia
Yu, Jianhua
Song, Yuxia
Chen, Hui
Wu, Hao
Qin, Shanfang
Li, Linghua
author_sort Huang, Xiaojie
collection PubMed
description The World Health Organization guidelines recommend lopinavir/ritonavir (LPV/r) as a second-line antiretroviral therapy (ART) for HIV-infected adults in middle-income and low-income countries as a protease inhibitor boost based on clinical trials; however, the real-world safety and efficacy remain unknown. Therefore, we conducted a large-scale, multicenter retrospective cohort study to evaluate the efficacy and safety of LPV/r-based ART among HIV-infected adults in China in whom first-line therapy failed. The data were obtained from a national database covering 17 clinics in China for six years of follow-up from 2009 to 2016. Failure of first-line treatment was determined according to a viral load at least 400 copies/ml at week 48, non-completers at week 48 for any reason, and those who switched ART before week 48 for any reason such as side effects. Treatment effectiveness was assessed by the rate of CD4(+)T cell recovery, defined as >500 cells/mm(3), and the proportion of patients achieving viral suppression, defined as <400 or <50 copies/ml according to the methods used during treatment. Safety was assessed by rates of LPV/r-related adverse events (AEs), including lipid disorder, severe abnormal liver function, myelosuppression, and renal function. Between 2009 and 2016, 1196 participants (median, 36 years old; IQR, 30–43 years) were ultimately enrolled. All patients had been on LPV/r-based second-line ART treatment for more than one year after failure of any first-line ART regimen. Overall CD4(+)T cell counts increased from 138 cells/mm(3) to 475 cells/mm(3) and 37.2% of all participants reached CD4 recovery. Viral suppression rates dramatically increased at the end of the first year (<400 copies/ml, 88.8%; <50 copies/ml, 76.7%) and gradually increased during follow-up (<400 copies/ml, 95.8%; <50 copies/ml, 94.4%). The most frequently reported AEs were LPV/r-induced lipid disorders with no obvious increase on LDL-C at follow-up visits. This is the first real-world LPV/r-based second-line treatment study to cover such a large population in China. These results provide strong clinical evidence that LPV/r-based second-line ART is effective in increasing CD4(+)T cell counts and viral suppression rates with tolerable side effects in HIV-infected adults in China in whom first-line treatment had failed.
format Online
Article
Text
id pubmed-6917650
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-69176502020-01-09 Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China Huang, Xiaojie Xu, Liumei Sun, Lijun Gao, Guiju Cai, Weiping Liu, Yanfen Ding, Haibo Wei, Hongxia Ma, Ping Wang, Min Liu, Shuiqing Chen, Yaokai Chen, Xiaohong Zhao, Qingxia Yu, Jianhua Song, Yuxia Chen, Hui Wu, Hao Qin, Shanfang Li, Linghua Front Pharmacol Pharmacology The World Health Organization guidelines recommend lopinavir/ritonavir (LPV/r) as a second-line antiretroviral therapy (ART) for HIV-infected adults in middle-income and low-income countries as a protease inhibitor boost based on clinical trials; however, the real-world safety and efficacy remain unknown. Therefore, we conducted a large-scale, multicenter retrospective cohort study to evaluate the efficacy and safety of LPV/r-based ART among HIV-infected adults in China in whom first-line therapy failed. The data were obtained from a national database covering 17 clinics in China for six years of follow-up from 2009 to 2016. Failure of first-line treatment was determined according to a viral load at least 400 copies/ml at week 48, non-completers at week 48 for any reason, and those who switched ART before week 48 for any reason such as side effects. Treatment effectiveness was assessed by the rate of CD4(+)T cell recovery, defined as >500 cells/mm(3), and the proportion of patients achieving viral suppression, defined as <400 or <50 copies/ml according to the methods used during treatment. Safety was assessed by rates of LPV/r-related adverse events (AEs), including lipid disorder, severe abnormal liver function, myelosuppression, and renal function. Between 2009 and 2016, 1196 participants (median, 36 years old; IQR, 30–43 years) were ultimately enrolled. All patients had been on LPV/r-based second-line ART treatment for more than one year after failure of any first-line ART regimen. Overall CD4(+)T cell counts increased from 138 cells/mm(3) to 475 cells/mm(3) and 37.2% of all participants reached CD4 recovery. Viral suppression rates dramatically increased at the end of the first year (<400 copies/ml, 88.8%; <50 copies/ml, 76.7%) and gradually increased during follow-up (<400 copies/ml, 95.8%; <50 copies/ml, 94.4%). The most frequently reported AEs were LPV/r-induced lipid disorders with no obvious increase on LDL-C at follow-up visits. This is the first real-world LPV/r-based second-line treatment study to cover such a large population in China. These results provide strong clinical evidence that LPV/r-based second-line ART is effective in increasing CD4(+)T cell counts and viral suppression rates with tolerable side effects in HIV-infected adults in China in whom first-line treatment had failed. Frontiers Media S.A. 2019-12-11 /pmc/articles/PMC6917650/ /pubmed/31920648 http://dx.doi.org/10.3389/fphar.2019.01455 Text en Copyright © 2019 Huang, Xu, Sun, Gao, Cai, Liu, Ding, Wei, Ma, Wang, Liu, Chen, Chen, Zhao, Yu, Song, Chen, Wu, Qin and Li http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Huang, Xiaojie
Xu, Liumei
Sun, Lijun
Gao, Guiju
Cai, Weiping
Liu, Yanfen
Ding, Haibo
Wei, Hongxia
Ma, Ping
Wang, Min
Liu, Shuiqing
Chen, Yaokai
Chen, Xiaohong
Zhao, Qingxia
Yu, Jianhua
Song, Yuxia
Chen, Hui
Wu, Hao
Qin, Shanfang
Li, Linghua
Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China
title Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China
title_full Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China
title_fullStr Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China
title_full_unstemmed Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China
title_short Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China
title_sort six-year immunologic recovery and virological suppression of hiv patients on lpv/r-based second-line antiretroviral treatment: a multi-center real-world cohort study in china
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917650/
https://www.ncbi.nlm.nih.gov/pubmed/31920648
http://dx.doi.org/10.3389/fphar.2019.01455
work_keys_str_mv AT huangxiaojie sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina
AT xuliumei sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina
AT sunlijun sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina
AT gaoguiju sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina
AT caiweiping sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina
AT liuyanfen sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina
AT dinghaibo sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina
AT weihongxia sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina
AT maping sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina
AT wangmin sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina
AT liushuiqing sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina
AT chenyaokai sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina
AT chenxiaohong sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina
AT zhaoqingxia sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina
AT yujianhua sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina
AT songyuxia sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina
AT chenhui sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina
AT wuhao sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina
AT qinshanfang sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina
AT lilinghua sixyearimmunologicrecoveryandvirologicalsuppressionofhivpatientsonlpvrbasedsecondlineantiretroviraltreatmentamulticenterrealworldcohortstudyinchina